STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACRS
  4. [Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity

Aclaris Therapeutics (ACRS) director gains new RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aclaris Therapeutics director Maxine Gowen reported equity compensation activity and an RSU vesting. On June 4, 2026, she received 10,987 Restricted Stock Units, each representing a right to one share of common stock, and a stock option for 42,350 shares at an exercise price of $4.71 per share. The option vests in twelve equal monthly installments starting July 4, 2026 under the company’s 2025 Equity Incentive Plan and non‑employee director compensation policy. On June 5, 2026, 11,580 RSUs vested and were converted into common stock at no cash cost, leaving Gowen with 33,334 common shares held directly. The filing shows awards and an RSU vesting, with no open‑market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider GOWEN MAXINE
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 11,580 $0.00 --
Exercise Common Stock 11,580 $0.00 --
Grant/Award Stock Option (Right to Buy) 42,350 $0.00 --
Grant/Award Restricted Stock Units 10,987 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 33,334 shares (Direct, null); Stock Option (Right to Buy) — 42,350 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. The shares underlying these restricted stock units vested on June 5, 2026.
RSUs vested and converted 11,580 shares RSUs vested into common stock on June 5, 2026 at $0.00
Common shares held after transactions 33,334 shares Direct ownership after June 5, 2026 RSU conversion
New RSU grant 10,987 units Restricted Stock Units granted June 4, 2026, vesting June 4, 2027
Stock option grant size 42,350 shares Option granted June 4, 2026, right to buy common stock
Stock option exercise price $4.71 per share Conversion or exercise price for 42,350-share option
Stock option expiration June 3, 2036 Expiration date of 42,350-share stock option grant
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of $4.7100 per share"
Continuous Service financial
"will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service"
2025 Equity Incentive Plan financial
"Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan)"
non-employee director compensation policy financial
"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GOWEN MAXINE
(Last)(First)(Middle)
C/O ACLARIS THERAPEUTICS, INC.
701 LEE ROAD, SUITE 103
(Street)
WAYNE PENNSYLVANIA 19087
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026M11,580A(1)33,334D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.7106/04/2026A42,350 (2)06/03/2036Common Stock42,350$042,350(3)D
Restricted Stock Units(1)06/04/2026A10,987 (4) (4)Common Stock10,987$010,987(3)D
Restricted Stock Units(1)06/05/2026M11,580 (5) (5)Common Stock11,580$00D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
2. The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
3. This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
4. The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
5. The shares underlying these restricted stock units vested on June 5, 2026.
/s/ Matthew Rothman, Attorney-in-Fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR